Background
Microsporidia of the genus
Encephalitozoon
are usually associated with severe infections in immunodeficient hosts while, in immunocompetent ones, microsporidiosis produces minimal clinically apparent disease. Despite their microscopic size, microsporidia are capable of causing systemic infection within a few days. However, the mechanisms by which microsporidia reach target tissues during acute infection remain unclear. Out of four genotypes of
Encephalitozoon cuniculi
, only three are available for experimental studies, with
E. cuniculi
genotype II being the best characterized.
Methods
In the present study, we tested the association between inflammation induction in immunocompetent and immunodeficient mice and the presence of spores of
E. cuniculi
genotypes I and III in selected organs using molecular methods and compared the results with previously published data on
E. cuniculi
genotype II.
Results
We reported the positive connection between inflammation induction and the significant increase of
E. cuniculi
genotypes I and III occurrence in inflammatory foci in both immunocompetent BALB/c and immunodeficient severe combined immunodeficient (SCID) mice in the acute phase of infection. The induction of inflammation resulted in increased concentration of
E. cuniculi
of both genotypes in the site of inflammation, as previously reported for
E. cuniculi
genotype II. Moreover, our study extended the spectrum of differences among
E. cuniculi
genotypes by the variations in dispersal rate within host bodies after experimentally induced inflammation.
Conclusion
The results imply possible involvement of immune cells serving as vehicles transporting
E. cuniculi
towards inflammation foci. The elucidation of possible connection with pro-inflammatory immune responses represents an important challenge with implications for human health and the development of therapeutic strategies.
We describe the prevalence of Pneumocystis jirovecii in mother-infant pairs of very low birth weight newborns <32 weeks gestation. Molecular and microscopic methods were used for detection of P. jirovecii in patients’ specimens. Pneumocystis DNA was detected in eight nasopharyngeal aspirates (14%) of 56 newborns and in seven oral washes (21%) of 34 mothers. Pneumocystis detection immediately after birth suggests the possibility of its transplacental transmission. Comparing to non-colonized infants, more frequent occurrence of bronchopulmonary dysplasia was seen in colonized ones (P=0.02), suggesting a potential clinical importance of this pathogen in abnormal lung development.
Objectives: Patients with inflammatory bowel disease (IBD) are susceptible to intestinal opportunistic infections due to both defective mucosal immunity and altered immune response resulting from immunosuppressive treatment. Microsporidia infecting the gastrointestinal tract and causing diarrhoea can potentially affect the course of IBD.Methods: Stool samples (90 IBD children and 121 healthy age-matched controls) were screened for Encephalitozoon spp. and Enterocytozoon bieneusi by microscopy and polymerase chain reaction followed by sequencing.Results:E. bieneusi genotype D was found in seven out of 90 (7.8%) IBD children. No children from the control group were infected, making the pathogen prevalence in the IBD group significant (P = 0.002). Furthermore, infection was confirmed only in patients receiving immunosuppressive treatment (P = 0.013).Conclusions: Children with IBD are at risk of intestinal E. bieneusi infection, especially when receiving immunosuppressive treatment. Therefore, microsporidia should be considered as a significant infectious agent in this group of patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.